These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27340349)

  • 1. Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer.
    Wen F; Li Q
    World J Gastroenterol; 2016 Jun; 22(23):5332-41. PubMed ID: 27340349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
    Zhang W; Gordon M; Lenz HJ
    Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab for treatment of metastatic colorectal cancer.
    Cerea G; Ricotta R; Schiavetto I; Maugeri MR; Sartore-Bianchi A; Moroni M; Artale S; Siena S
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii66-7. PubMed ID: 16760297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    Xu W; Jing H; Zhang F
    Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
    JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
    Lee D
    Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399
    [No Abstract]   [Full Text] [Related]  

  • 8. Cetuximab: appraisal of a novel drug against colorectal cancer.
    Hildebrandt B; le Coutre P; Nicolaou A; Köble K; Riess H; Dörken B
    Recent Results Cancer Res; 2007; 176():135-43. PubMed ID: 17607921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies.
    de Mello RA; Marques AM; Araújo A
    World J Gastroenterol; 2013 Oct; 19(38):6315-8. PubMed ID: 24151349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
    Cleary JM; McRee AJ; Shapiro GI; Tolaney SM; O'Neil BH; Kearns JD; Mathews S; Nering R; MacBeath G; Czibere A; Sharma S; Korn WM
    Invest New Drugs; 2017 Feb; 35(1):68-78. PubMed ID: 27853996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab in the treatment of patients with colorectal cancer.
    Garrett CR; Eng C
    Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
    J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab in the treatment of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Expert Opin Biol Ther; 2007 Feb; 7(2):243-56. PubMed ID: 17250462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.
    Jeong WJ; Cha PH; Choi KY
    World J Gastroenterol; 2014 Aug; 20(29):9862-71. PubMed ID: 25110417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.
    Santoro V; Jia R; Thompson H; Nijhuis A; Jeffery R; Kiakos K; Silver AR; Hartley JA; Hochhauser D
    J Natl Cancer Inst; 2016 Jun; 108(6):djv394. PubMed ID: 26719345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
    Watkins D; Cunningham D
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S47-52. PubMed ID: 18021487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.